J&J Q1 ’17 Earnings Update
J&J presented its Q1 ’17 earnings results and provided a brief update to its diabetes business including drugs and devices. Of note, J&J is hosting its Pharmaceutical Business Review on May 17.
J&J presented its Q1 ’17 earnings results and provided a brief update to its diabetes business including drugs and devices. Of note, J&J is hosting its Pharmaceutical Business Review on May 17.
The ClincalTrials.gov record for the CREDENCE trial has been updated to reflect a later primary completion date. The estimated primary completion date has been pushed back from February 11, 2019 to June 28, 2019, which may be due to trial recruitment.
EMA has issued a warning that Invokana is associated with increased cases of lower limb amputations, particularly toes, in the CANVAS and CANVAS-R studies. The underlying cause remains unknown. While EMA has concluded the risk exists, the issue remains under investigation with FDA.